Galera Therapeutics, Inc. (GRTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.7700 |
| Open | 1.7900 |
| Bid | 1.8700 x 1200 |
| Ask | 1.9000 x 1000 |
| Day's Range | 1.6200 - 1.7985 |
| 52 Week Range | 1.1500 - 10.7900 |
| Volume | |
| Avg. Volume | 220,379 |
| Market Cap | 44.792M |
| Beta (5Y Monthly) | 2.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9460 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GRTX
Related Research
- Galera Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 06/07/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat11 months agoArgus Research
- American City Business Journals
Galera shares surge on news it will seek OK for lead drug candidate by year's end
The experimental therapy is designed to treat a side effect of radiation therapy in cancer patients.
- GlobeNewswire
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates
Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of avasopasem for SOM will be presented in an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Reported positive topline results from its Phase 2a AESOP trial of avasopasem for chemoradiotherapy-induced esophagitis MALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- G
- GlobeNewswire
Galera Announces Plan to Submit Avasopasem NDA by Year End
After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of 2022MALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced its intent to file a New Drug Application (NDA)
